Headquartered at Fred Hutch in Seattle, the Network includes over 70 sites on four continents staffed by teams with expertise in vaccinology, immunology, and in conducting clinical trials.
For more than 20 years, the HVTN has conducted all phases of clinical trials based on the latest developments in vaccinology and immunology for the prevention of HIV, tuberculosis and COVID-19.
We are investing in the next generation of HIV prevention researchers with grants and mentoring for African American/Black and Hispanic/Latinx medical students.
Our mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV globally.
We are the world’s largest publicly-funded international collaboration focused on the evaluation of vaccines to prevent HIV/AIDS.
Our sites conduct all phases of clinical trials — from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy.
Worldwide, thousands of people have participated in HIV vaccine trials. Volunteers are the heroes of vaccine development.
The HIV Vaccine Trials Network is an international partnership of research scientists, clinical trial sites, laboratories, statisticians, regulators and ethicists, participants, volunteers and community representatives working with industry, academia, and governments in the global search for a preventive HIV vaccine.
HVTN Leadership recognizes clinical site staff and affiliated individuals who have made significant contributions to the Network. Please join the HVTN in congratulating the 2023 awards recipients.
Reflections on the lives and immeasurable contributions of friends and colleagues Jorge Beloqui, Kirk D. Myers-Hill and Douglas Silva. Your legacies will live on in the hearts of those at the HVTN and beyond.
In this issue, we acknowledge the recent passing of our dear colleague and long-time HIV activist Giulio Corbelli, a recent announcement of Dr. Anthony Fauci stepping down from his role as Director of NIAID, a recent statement from experts regarding the importance of including people living with HIV in TB research, along with many other HVTN updates.